V. Currie

发表

Sequential adjuvant therapy with doxorubicin/paclitaxel/cyclophosphamide for resectable breast cancer involving four or more axillary nodes.

C. Hudis, J. Baselga, D. Lebwohl, 1995, Seminars in oncology.

Effect of adjuvant breast cancer chemotherapy on cognitive function from the older patient’s perspective

J. Holland, C. Hudis, L. Norton, 2006, Breast Cancer Research and Treatment.

Endocrine consequences of CMF adjuvant therapy in premenopausal and postmenopausal breast cancer patients

A. Dnistrian, M. Schwartz, A. Fracchia, 1983, Cancer.

Dose-dense therapy with weekly 1-hour paclitaxel infusions in the treatment of metastatic breast cancer.

C. Hudis, L. Norton, J. Baselga, 1998, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Association of disease‐free survival and percent of ideal dose in adjuvant breast chemotherapy

N. Geller, G. Petroni, V. Currie, 1990, Cancer.

Phase I evaluation of tetrahydrouridine combined with cytosine arabinoside.

J. Burchenal, C. Tan, I. Krakoff, 1979, Cancer treatment reports.

The combined use of radiation therapy and lonidamine in the treatment of brain metastases

G. Krol, L. Deangelis, J. Posner, 1989, Journal of Neuro-Oncology.

Lack of increased cardiac toxicity with sequential doxorubicin and paclitaxel.

C. Hudis, L. Norton, J. Baselga, 1998, Cancer investigation.

Initial clinical studies of piritrexim.

J. Laszlo, N. Clendeninn, T. Williams, 1987, NCI monographs : a publication of the National Cancer Institute.

Phase I and clinical pharmacologic evaluation of Lonidamine in patients with advanced cancer.

J. H. Kim, V. Currie, C. Young, 1984, Oncology.

Fatal neutropenia associated with long-term tamoxifen therapy

V. Currie, T. Gee, V. Miké, 1994, The Lancet.

Weekly T rastuzumab a nd P aclitaxel T herapy f or M etastatic Breast C ancer W ith A nalysis o f E fficacy b y HER2 Immunophenotype a nd G ene A mplification

G. Hortobagyi, C. Hudis, L. Norton, 2001 .

EXPERIMENTAL AND CLINICAL STUDIES ON NUCLEOSIDE ANALOGS AS ANTITUMOR AGENTS *

J. Burchenal, I. Krakoff, V. Currie, 1975, Annals of the New York Academy of Sciences.

Phase II study of vindesine sulfate in the therapy for advanced renal carcinoma.

A. Yagoda, V. Currie, C. Young, 1977, Cancer treatment reports.

Clinical pharmacologic and therapeutic studies of bleomycin given by continuous infusion

E. Cvitkovic, I. Krakoff, V. Currie, 1977, Cancer.

Sequential adjuvant therapy: the Memorial Sloan-Kettering Cancer Center experience.

C. Hudis, L. Norton, J. Baselga, 1996, Seminars in oncology.

A clinical trial of amygdalin (Laetrile) in the treatment of human cancer.

T. Fleming, L. Kvols, J. Rubin, 1982, The New England journal of medicine.

A clinical trial of amygdalin (Laetrile) in the treatment of human cancer.

T. Fleming, L. Kvols, J. Rubin, 1982, The New England journal of medicine.

Animal and clinical studies of 5-fluorouridine (fur). Abstr.

J. Burchenal, I. Krakoff, V. Currie, 1975 .

Ninety-six-hour paclitaxel infusion after progression during short taxane exposure: a phase II pharmacokinetic and pharmacodynamic study in metastatic breast cancer.

L. Norton, J. Baselga, P. Francis, 1996, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Weekly trastuzumab and paclitaxel therapy for metastatic breast cancer with analysis of efficacy by HER2 immunophenotype and gene amplification.

K S Panageas, G. Hortobagyi, C. Hudis, 2001, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Paclitaxel and recombinant human granulocyte colony-stimulating factor as initial chemotherapy for metastatic breast cancer.

C. Hudis, J. Crown, D. Lebwohl, 1993, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Phase I trial of vindesine in patients with advanced cancer.

I. Krakoff, V. Currie, C. Young, 1978, Cancer treatment reports.

A phase II trial of gemcitabine in patients with metastatic breast cancer previously treated with an anthracycline and taxane.

D. Lake, C. Hudis, L. Norton, 2005, Clinical breast cancer.

Dose-dense (DD) doxorubicin and cyclophosphamide (AC) followed by weekly paclitaxel (P) with trastuzumab (T) and lapatinib (L) in HER2/neu-positive breast cancer is not feasible due to excessive diarrhea: updated results.

D. Lake, C. Hudis, L. Norton, 2009 .

Phase II study of semisynthetic paclitaxel in metastatic breast cancer.

G. Hortobagyi, C. Hudis, L. Norton, 1997, European journal of cancer.

A prospective randomized comparison of epirubicin and doxorubicin in patients with advanced breast cancer.

N. Geller, G. Petroni, E. Casper, 1985, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Phase II and pharmacologic study of docetaxel as initial chemotherapy for metastatic breast cancer.

C. Hudis, L. Norton, J. Baselga, 1996, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Phase II trial of paclitaxel by 3-hour infusion as initial and salvage chemotherapy for metastatic breast cancer.

C. Hudis, J. Crown, A. Seidman, 1995, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Paclitaxel as second and subsequent therapy for metastatic breast cancer: activity independent of prior anthracycline response.

C. Hudis, J. Baselga, J. Crown, 1995, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Taxol plus recombinant human granulocyte colony stimulating factor as salvage chemotherapy for metastatic breast cancer

C. Hudis, L. Norton, S. Arbuck, 1994 .

Taxol and Recombinant Human Granulocyte Colony‐Stimulating Factor, an Active Regimen as Initial Therapy for Metastatic Breast Cancer

C. Hudis, L. Norton, S. Arbuck, 1993, Annals of the New York Academy of Sciences.

Phase II Study of Feasibility of Dose-Dense FEC Followed by Alternating Weekly Taxanes in High-Risk, Four or More Node-Positive Breast Cancer

D. Lake, C. Hudis, L. Norton, 2004, Clinical Cancer Research.

Phase II evaluation of orally administered idarubicin in patients with advanced breast cancer.

E. Casper, V. Currie, T. Hakes, 1987, Cancer treatment reports.

Prevalence, predictors, and course of anticipatory nausea in women receiving adjuvant chemotherapy for breast cancer

J. Holland, P. Jacobsen, M. Andrykowski, 1988, Cancer.

5-year results of dose-intensive sequential adjuvant chemotherapy for women with high-risk node-positive breast cancer: A phase II study.

C. Hudis, L. Norton, M. Theodoulou, 1999, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Doxorubicin followed by sequential paclitaxel and cyclophosphamide versus concurrent paclitaxel and cyclophosphamide: 5-year results of a phase II randomized trial of adjuvant dose-dense chemotherapy for women with node-positive breast carcinoma.

C. Hudis, L. Norton, M. Theodoulou, 2001, Clinical cancer research : an official journal of the American Association for Cancer Research.

A Prospective, Longitudinal Study of the Functional Status and Quality of Life of Older Patients with Breast Cancer Receiving Adjuvant Chemotherapy

M. Theodoulou, Clifford Hudis, M. Moasser, 2006, Journal of the American Geriatrics Society.

Nonpharmacologic factors in the development of posttreatment nausea with adjuvant chemotherapy for breast cancer

J. Holland, P. Jacobsen, M. Andrykowski, 1988, Cancer.

Protein binding of brequinar in the plasma of healthy donors and cancer patients and analysis of the relationship between protein binding and pharmacokinetics in cancer patients

J. Bertino, H. Pieniaszek, Cecilia L Chi, 2004, Cancer Chemotherapy and Pharmacology.

The safety of dose-dense doxorubicin and cyclophosphamide followed by paclitaxel with trastuzumab in HER-2/neu overexpressed/amplified breast cancer.

D. Lake, C. Hudis, L. Norton, 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Phase II trial of carboplatin and etoposide in metastatic breast cancer

C. Hudis, L. Norton, J. Crown, 1993, Cancer.

Dose-dense therapy with paclitaxel via weekly 1-hour infusion: preliminary experience in the treatment of metastatic breast cancer.

C. Hudis, L. Norton, M. Theodoulou, 1997, Seminars in oncology.

Practical guidelines for routine intensity-modulated radiotherapy verification: pre-treatment verification with portal dosimetry and treatment verification with in vivo dosimetry.

D Huyskens, A Van Esch, D. Huyskens, 2010, The British journal of radiology.

Phase II evaluation of pyrazofurin in patients with carcinoma of the lung.

R. Wittes, R. Gralla, R. Golbey, 1978, Cancer treatment reports.

Taxol plus recombinant human granulocyte-colony stimulating factor as initial and as salvage chemotherapy for metastatic breast cancer: a preliminary report.

J. Crown, D. Lebwohl, A. Seidman, 1993, Journal of the National Cancer Institute. Monographs.